🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Our latest feature is out now! 🎉 Learn more about how CAR-T is changing the treatment landscape for hematologic malignancies, with insight from Kai Rejeski, Tania Jain, Michael Jain, and Joshua Brody, MD. 📚 buff.ly/IU7K4ul

I really applaud this effort, we urgently need to reduce the bloat of our clinical trials.

Some patients have prolonged neurotoxicity after CAR T cell therapy but usually recover in time. I provided a commentary on the UPenn experience: url.us.m.mimecastprotect.com/s/ibx9CW6WkJs5… pubmed.ncbi.nlm.nih.gov/39848443/

We sometimes see this for several weeks after CAR T cell therapy, which is also associated with high IL-6 levels

Imagine fellowship in Hawaii! I bet more than 59% of fellows would stay.

🚨Hot off the press 🚨 A lesser-known vulnerability in CAR T-cell therapy: Sarcopenia. New in CCR AACR Predicts ↑ NRM 1/3 patients lose >10% muscle by D30 Linked to fatty acid catabolism With Michael Jain Kai Rejeski MariSubklewe Frederick L. Locke pubmed.ncbi.nlm.nih.gov/40238583/

Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial | Genetics and Genomics | JAMA Oncology | JAMA Network jamanetwork.com/journals/jamao…

First report on TIL therapy resistance in lung cancer! 📰 👉nature.com/articles/s4301… We show subclonal neoantigens are lost on progression; & antigen-specific TIL decay in non-responders. Proud of our team, and thanks to Stand Up To Cancer for funding! Nature Cancer @moffittnews

#Myeloma Paper of the Day: Dysregulated immune proteins in plasma (SLAMF7, TNFRSF17 (BCMA), QPCT, SLAMF1, CNTN5, BAFF (TNFSF13B)) in the UK Biobank may predict myeloma up to 12 years before clinical diagnosis: pubmed.ncbi.nlm.nih.gov/40334107/. #mmsm

For me, ⁦Marco Ruella⁩ is the best scientist in our field right now. Fantastic to host him ⁦Moffitt Cancer Center⁩ ⁦Frederick L. Locke⁩ today in Tampa

Congratulations to ⁦Frederick L. Locke⁩ on winning the ⁦Moffitt Cancer Center⁩ Researcher of the Year Award and giving a virtuoso overview of his achievements over the past 10 years! With ⁦Mihaela Druta⁩

This work models car t neurotoxicity in mice and finds that the macrophages in the brain (microglia) get inflamed as a key pathologic mechanism. This makes a lot of sense, since in the rest of the body macrophages also sustain cytokine toxicity.

Startling result- FDA committee (consisting of non-FDA members) did not like it that only a small n of patients (n=25) were in N. America and that results in EU/US were not positive compared to results in Asia. Clarity needed on what is the “applicability” standard going forward

From the May issue: GPR65 Inactivation in Tumor Cells Drives Antigen-Independent CAR-T Cell Resistance via Macrophage Remodeling brnw.ch/21wSZir By Jayadev Mavuluri, Yogesh Dhungana (Pronounced: Dhung-gä-nä), Jiyang Yu, Terrence Geiger, and colleagues. St. Jude Research

👉 Latest Science from #ASCO25: Michael Jain, MD, PhD (Michael Jain ) shares new data validating end-of-treatment ctDNA-MRD testing using PhasED-Seq in DLBCL. Findings support ctDNA-MRD as a powerful predictor of relapse and survival in first-line treatment. Read more:

This is similar to car t in lymphoma… “plateau envy” no more?

I did not know this. Was this already known? Seems like a huge finding. <1% of tumor antigens come from mutated sequences.

#FollowFriday Meet Michael Jain, MD, PhD (Michael Jain), Associate Member and ICE-T Medical Director in the department of Blood & Marrow Transplant and Cellular Immunotherapy. He’s an expert in relapsed lymphoma, stem cell transplants and cutting-edge immunotherapy. Follow him

🚨 New Preprint 🚨 A continuous landscape of signaling encodes a corresponding landscape of CAR T cell phenotype How can we tune JAK/STAT signaling to create better immune cell therapies? doi.org/10.1101/2025.0…

48h since lab destroyed 😭😭 People safe, thx god. Deeply thankful Michael Baumann, MD DKFZ & Otmar_Wiestler HelmholtzAssociation for reaching out to us w leadership & support. Will continue updating on support and leadership, while considering w colleagues our next chapter- suggestions?